journal article·2019-12

Pentapeptide-decorated silica nanoparticles loading salmon calcitonin for in vivo osteoporosis treatment with sustained hypocalcemic effect

P. Yu, Y. Chen, Y. Wang, Y. Liu, P. Zhang, Q. Guo, S. Li, H. Xiao, J. Xie, H. Tan, J. Li

Publisher page

Abstract

Abstract Patients with osteoporosis are at a constant risk of bone fracture, and traditional treatment involves the administration of anabolic or antiresorptive drugs. At present, antiosteoporosis drugs, including salmon calcitonin (sCT), face many challenges such as short half-life and limited therapeutic efficiency to suppress bone loss and increase bone mass. Therefore, strategies to prolong the action time of antiosteoporosis drugs in vivo and improve their efficacy are essential. In this study, pentapeptide-decorated silica nanoparticles were synthesized and loaded with sCT (SiO2-Pep@sCT) to improve the therapeutic efficiency. Cytotoxicity and proliferation tests confirmed that SiO2-Pep@sCT had excellent biocompatibility. Biomarkers, including alkaline phosphatase activity, calcium flux, and calcified nodules, showed that SiO2-Pep@sCT promoted osteogenic differentiation in osteoblasts. Further, in vivo evaluations revealed that SiO2-Pep@sCT can efficiently prolong the half-life of sCT (from 30.5 to 69.3 min), leading to the maintenance of serum calcium in the normal physiological range in 48 h after single injection. For long-term treatment, micro-CT analysis showed that SiO2-Pep@sCT can enhance trabeculation and accelerate the process of bone repair during osteoporosis. Thus, the SiO2-Pep nanoparticle with uniform charge spatially distributed on the surface might be a potential drug/protein carrier for treating osteoporosis or other clinic diseases.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone health and osteoporosis research · Bone health and treatments · Vitamin D Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. Mediating effects on health-related quality of life in adults with osteoporosis: a structural equation modeling10.1007/s00198-014-2963-3 ↗
2. Computational anatomy in the study of bone structure10.1007/s11914-013-0148-1 ↗
3. Osteoporosis: now and the future10.1016/S0140-6736(10)62349-5 ↗
4. WNT signaling in bone homeostasis and disease: from human mutations to treatments10.1038/nm.3074 ↗
5. European guidance for the diagnosis and management of osteoporosis in postmenopausal women10.1007/s00198-012-2074-y ↗
6. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture10.1038/nature14878 ↗
7. In situ self-assembling micellar depots that can actively trap and passively release NO with long-lasting activity to reverse osteoporosis10.1002/adma.201705605 ↗
8. Glucocorticoid-induced osteoporosis10.1016/j.biopha.2004.08.018 ↗
9. An overview and management of osteoporosis10.5152/eurjrheum.2016.048 ↗
10. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial10.1016/S0140-6736(17)32640-5 ↗
11. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis10.1007/s00223-006-0019-1 ↗
12. Update on glucocorticoid-induced osteoporosis10.1016/j.rdc.2011.07.003 ↗
13. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis10.1007/s001980200108 ↗
14. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment
15. Salmon calcitonin: a review of current and future therapeutic indications10.1007/s00198-007-0490-1 ↗
16. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica10.1007/BF02529727 ↗
17. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis10.1002/14651858.CD001983 ↗
18. Experimental research into the potential therapeutic effect of GYY4137 on Ovariectomy-induced osteoporosis10.1186/s11658-018-0114-0 ↗
19. 2nd, calcitonin stewardship strategies
20. Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery10.1016/j.jconrel.2009.12.011 ↗
21. In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin
22. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies10.1007/s11095-009-0015-z ↗
23. Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles10.3109/02652040902751125 ↗
24. Salmon calcitonin-loaded PLGA microspheres/calcium phosphate cement composites for osteoblast proliferation10.1002/app.45486 ↗
25. Calcitonin-loaded thermosensitive hydrogel for long-term antiosteopenia therapy10.1021/acsami.7b05740 ↗
26. Biodegradable and thermoreversible PCLA-PEG-PCLA hydrogel as a barrier for prevention of post-operative adhesion10.1016/j.biomaterials.2011.03.046 ↗
27. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells10.1016/j.ijpharm.2013.05.025 ↗
28. Thermoresponsive nanogels for prolonged duration local anesthesia10.1016/j.actbio.2012.06.013 ↗
29. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis10.1016/j.biomaterials.2011.08.042 ↗
30. Macrophage silica nanoparticle response is phenotypically dependent10.1016/j.biomaterials.2015.02.070 ↗
31. Novel biodegradable nanocarriers for enhanced drug delivery10.4155/tde-2016-0051 ↗
32. Mesoporous silicon-PLGA composite microspheres for the double controlled release of biomolecules for orthopedic tissue engineering10.1002/adfm.201100403 ↗
33. Spherical silica micro/nanomaterials with hierarchical structures: synthesis and applications10.1039/c1nr10660k ↗
34. Biocompatibility assessment of Si-based nano- and micro-particles10.1016/j.addr.2012.05.008 ↗
35. Sol-Gel processing of silica nanoparticles and their applications10.1016/j.cis.2014.10.007 ↗
36. Bone remodeling-inspired dual delivery electrospun nanofibers for promoting bone regeneration10.1039/C8NR07329E ↗
37. Mesoporous silica nanoparticles in injectable hydrogels: factors influencing cellular uptake and viability10.1039/C7NR02015E ↗
38. Influence of mesopore size and peptide aggregation on the adsorption and release of a model antimicrobial peptide onto/from mesoporous silica nanoparticles in vitro10.1039/C7ME00059F ↗
39. Self-assembled peptide-based nanomaterials for biomedical imaging and therapy10.1002/adma.201703444 ↗
40. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications10.1039/C7CS00877E ↗
41. Transdermal delivery of peptide and protein drugs: an overview10.1002/aic.690410814 ↗
42. Theoretical modelling of mass spectrometric behaviour of peptides: singly and doubly protonated tetraglycine10.1002/(SICI)1097-0231(199609)10:12<1485::AID-RCM710>3.0.CO;2-Y ↗
43. SDS-induced peptide conformational changes: from triglycyl-glycine to amyloid-β oligomers associated with alzheimer's disease10.1007/s10989-015-9483-7 ↗
44. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release10.1016/j.jconrel.2017.04.014 ↗
45. Controlling particle size in the Stöber process and incorporation of calcium10.1016/j.jcis.2016.01.065 ↗
46. Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles10.1016/j.ijpharm.2018.12.053 ↗
47. Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis10.1016/j.yexmp.2014.10.004 ↗
48. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems10.1016/j.addr.2006.09.007 ↗
49. Mathematical modeling of drug delivery10.1016/j.ijpharm.2008.09.004 ↗
50. Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes10.1016/j.bbapap.2005.04.008 ↗
51. A novel spectrofluorimetric method for the determination of calcitonin in ampules through derivatization with fluorescamine10.1002/bio.2467 ↗
52. Bioactive effects of silica nanoparticles on bone cells are size, surface, and composition dependent10.1016/j.actbio.2018.10.018 ↗
53. 3D superelastic scaffolds constructed from flexible inorganic nanofibers with self-fitting capability and tailorable gradient for bone regeneration10.1002/adfm.201901407 ↗
54. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study10.1136/ard.2003.011734 ↗
55. Nebivolol enhances the effect of alendronate against methylprednisolone-induced osteoporosis in rats
56. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats10.1016/j.jconrel.2011.09.096 ↗
57. Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats10.3892/mmr.2015.3637 ↗
58. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism10.1016/j.bone.2008.07.003 ↗